Cargando…

Evaluation of MUC1, MUC2, MUC5AC, and MUC6 Expression Differences in Lung Adenocarcinoma Subtypes by Using a Final Immunoreactivity Score (FIRS)

Objective: Lung adenocarcinomas are divided into acinar, lepidic, papillary, micropapillary, and solid predominant subtypes according to the current World Health Organization (WHO) classification. We designed this retrospective study to demonstrate profiles of MUC expression (MUC1, MUC2, MUC5AC, and...

Descripción completa

Detalles Bibliográficos
Autores principales: Buyuk, Melek, Ozluk, Yasemin, Vurallı Bakkaloglu, Dogu, Ozkan, Berker, Fırat, Pinar, Yılmazbayhan, Dilek
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Federation of Turkish Pathology Societies 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10518128/
https://www.ncbi.nlm.nih.gov/pubmed/36367122
http://dx.doi.org/10.5146/tjpath.2022.01593
_version_ 1785109446214549504
author Buyuk, Melek
Ozluk, Yasemin
Vurallı Bakkaloglu, Dogu
Ozkan, Berker
Fırat, Pinar
Yılmazbayhan, Dilek
author_facet Buyuk, Melek
Ozluk, Yasemin
Vurallı Bakkaloglu, Dogu
Ozkan, Berker
Fırat, Pinar
Yılmazbayhan, Dilek
author_sort Buyuk, Melek
collection PubMed
description Objective: Lung adenocarcinomas are divided into acinar, lepidic, papillary, micropapillary, and solid predominant subtypes according to the current World Health Organization (WHO) classification. We designed this retrospective study to demonstrate profiles of MUC expression (MUC1, MUC2, MUC5AC, and MUC6) of different histologic patterns within the same tumor among pulmonary adenocarcinomas and investigate correlations of MUC expression with clinicopathologic features. Material and Method: We analyzed the expression of mucins (MUC1, MUC2, MUC5AC, and MUC6) in a series of 99 resected lung adenocarcinomas, which included a total of 193 patterns (71 acinar, 30 lepidic, 25 papillary, 20 micropapillary, 34 solid and 13 mucinous) and calculated a final immune reactivity score (FIRS) per tumor. Results: MUC1 IRS scores were significantly higher in lepidic and solid patterns compared with mucinous patterns (p=0.013). MUC2 expression was seen only in three cases (1 acinar, 2 mucinous). MUC5AC and MUC2 expression was more common in mucinous patterns (p<0.001 and p=0.028, respectively). MUC6 expression was only detected in seven patterns and the expression was weak. No significant difference was seen among histologic patterns for the staining scores of MUC6. Mucinous adenocarcinoma differed from other histologic subtypes regarding MUC1 and MUC5AC expression. Mucinous adenocarcinoma showed less MUC1 expression with lower IRS scores and higher MUC5AC expression. Tumor size (p=0.006), lymphatic invasion (p=0.018), vascular invasion (p=0.025), perineural invasion (p=0.019), MUC1 IRS scores (p=0.018), and MUC1 IRS scores >8.5 (p=0.018) were significant predictors for lymph node metastasis. Conclusion: An alternative scoring for MUC1 can be used as a predictor for lymph node metastasis regardless of the histologic subtype.
format Online
Article
Text
id pubmed-10518128
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Federation of Turkish Pathology Societies
record_format MEDLINE/PubMed
spelling pubmed-105181282023-09-25 Evaluation of MUC1, MUC2, MUC5AC, and MUC6 Expression Differences in Lung Adenocarcinoma Subtypes by Using a Final Immunoreactivity Score (FIRS) Buyuk, Melek Ozluk, Yasemin Vurallı Bakkaloglu, Dogu Ozkan, Berker Fırat, Pinar Yılmazbayhan, Dilek Turk Patoloji Derg Original Article Objective: Lung adenocarcinomas are divided into acinar, lepidic, papillary, micropapillary, and solid predominant subtypes according to the current World Health Organization (WHO) classification. We designed this retrospective study to demonstrate profiles of MUC expression (MUC1, MUC2, MUC5AC, and MUC6) of different histologic patterns within the same tumor among pulmonary adenocarcinomas and investigate correlations of MUC expression with clinicopathologic features. Material and Method: We analyzed the expression of mucins (MUC1, MUC2, MUC5AC, and MUC6) in a series of 99 resected lung adenocarcinomas, which included a total of 193 patterns (71 acinar, 30 lepidic, 25 papillary, 20 micropapillary, 34 solid and 13 mucinous) and calculated a final immune reactivity score (FIRS) per tumor. Results: MUC1 IRS scores were significantly higher in lepidic and solid patterns compared with mucinous patterns (p=0.013). MUC2 expression was seen only in three cases (1 acinar, 2 mucinous). MUC5AC and MUC2 expression was more common in mucinous patterns (p<0.001 and p=0.028, respectively). MUC6 expression was only detected in seven patterns and the expression was weak. No significant difference was seen among histologic patterns for the staining scores of MUC6. Mucinous adenocarcinoma differed from other histologic subtypes regarding MUC1 and MUC5AC expression. Mucinous adenocarcinoma showed less MUC1 expression with lower IRS scores and higher MUC5AC expression. Tumor size (p=0.006), lymphatic invasion (p=0.018), vascular invasion (p=0.025), perineural invasion (p=0.019), MUC1 IRS scores (p=0.018), and MUC1 IRS scores >8.5 (p=0.018) were significant predictors for lymph node metastasis. Conclusion: An alternative scoring for MUC1 can be used as a predictor for lymph node metastasis regardless of the histologic subtype. Federation of Turkish Pathology Societies 2023-01-15 /pmc/articles/PMC10518128/ /pubmed/36367122 http://dx.doi.org/10.5146/tjpath.2022.01593 Text en Copyright © 2023 The Author(s). https://creativecommons.org/licenses/by/4.0/This is an open-access article published by Federation of Turkish Pathology Societies under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium or format, provided the original work is properly cited. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Original Article
Buyuk, Melek
Ozluk, Yasemin
Vurallı Bakkaloglu, Dogu
Ozkan, Berker
Fırat, Pinar
Yılmazbayhan, Dilek
Evaluation of MUC1, MUC2, MUC5AC, and MUC6 Expression Differences in Lung Adenocarcinoma Subtypes by Using a Final Immunoreactivity Score (FIRS)
title Evaluation of MUC1, MUC2, MUC5AC, and MUC6 Expression Differences in Lung Adenocarcinoma Subtypes by Using a Final Immunoreactivity Score (FIRS)
title_full Evaluation of MUC1, MUC2, MUC5AC, and MUC6 Expression Differences in Lung Adenocarcinoma Subtypes by Using a Final Immunoreactivity Score (FIRS)
title_fullStr Evaluation of MUC1, MUC2, MUC5AC, and MUC6 Expression Differences in Lung Adenocarcinoma Subtypes by Using a Final Immunoreactivity Score (FIRS)
title_full_unstemmed Evaluation of MUC1, MUC2, MUC5AC, and MUC6 Expression Differences in Lung Adenocarcinoma Subtypes by Using a Final Immunoreactivity Score (FIRS)
title_short Evaluation of MUC1, MUC2, MUC5AC, and MUC6 Expression Differences in Lung Adenocarcinoma Subtypes by Using a Final Immunoreactivity Score (FIRS)
title_sort evaluation of muc1, muc2, muc5ac, and muc6 expression differences in lung adenocarcinoma subtypes by using a final immunoreactivity score (firs)
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10518128/
https://www.ncbi.nlm.nih.gov/pubmed/36367122
http://dx.doi.org/10.5146/tjpath.2022.01593
work_keys_str_mv AT buyukmelek evaluationofmuc1muc2muc5acandmuc6expressiondifferencesinlungadenocarcinomasubtypesbyusingafinalimmunoreactivityscorefirs
AT ozlukyasemin evaluationofmuc1muc2muc5acandmuc6expressiondifferencesinlungadenocarcinomasubtypesbyusingafinalimmunoreactivityscorefirs
AT vurallıbakkalogludogu evaluationofmuc1muc2muc5acandmuc6expressiondifferencesinlungadenocarcinomasubtypesbyusingafinalimmunoreactivityscorefirs
AT ozkanberker evaluationofmuc1muc2muc5acandmuc6expressiondifferencesinlungadenocarcinomasubtypesbyusingafinalimmunoreactivityscorefirs
AT fıratpinar evaluationofmuc1muc2muc5acandmuc6expressiondifferencesinlungadenocarcinomasubtypesbyusingafinalimmunoreactivityscorefirs
AT yılmazbayhandilek evaluationofmuc1muc2muc5acandmuc6expressiondifferencesinlungadenocarcinomasubtypesbyusingafinalimmunoreactivityscorefirs